The findings published in Lancet in SPPORT trial, an international, multicentre, randomised phase 3 trial. The patients after prostatectomy for prostate cancer who had a persistently detectable or an initially undetectable and rising PSA of between 0·1 and 2·0 ng/mL were enrolled. The trial had 3 study groups.
The primary endpoint was freedom from cancer progression. The cancer progression was defined as biochemical failure according to the Phoenix definition (PSA ≥2 ng/mL over the nadir PSA). The PSA is used as a prostate cancer marker to follow cancer progression. The progression was also defined as clinical failure (local, regional, or distant), or death from any cause.
The group with triple therapy seems performed better. There was benefit of adding short term hormonal therapy (4-6 months ADT) and pelvic lymph node radiation to the prostate bed radiation therapy.
There were some acute adverse events in initial 3 months, however, the late toxicity (>3 months after radiotherapy) did not differ significantly between the groups.
https://pubmed.ncbi.nlm.nih.gov/35569466/
